Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigmentosa and Stargardt disease next year and a third BLA for geographic atrophy in 2028.
Speaking during a Piper Sandler discussion with analyst Biren Amin, Shankar said Ocugen is focused on inherited retinal diseases and dry age-related macular degeneration, including retinitis pigmentosa, Stargardt disease and geographic atrophy, the late form of dry AMD. He cited more than 100,000 retinitis pigmentosa patients in the U.S., about 50,000 Stargardt disease patients in the U.S. and 2 million to 3 million geographic atrophy patients in the U.S. and EU in the late stage of disease.
Get Ocugen alerts:
Shankar said Ocugen has retinitis pigmentosa and Stargardt programs in Phase 3 and expects to begin a global Phase 3 program for geographic atrophy in the third quarter, with alignment from regulators in the U.S. and Europe.
OCU410 Phase 3 Plans for Geographic Atrophy Amin began by asking about OCU410, Ocugen’s gene therapy candidate for geographic atrophy. Shankar said the therapy uses a modified RORA gene, which Ocugen is also using in its Stargardt program. He said RORA is intended to regulate multiple pathways involved in disease progression, including oxidative stress, lipid metabolism, inflammation and the complement system.
Shankar contrasted the approach with currently approved therapies that target the complement system, saying Ocugen believes RORA could help “reset” cellular homeostasis and create a healthier environment for photoreceptors and retinal pigment epithelial cells. He said Phase 2 data showed treatment benefit in one year, while many trials in the disease area run for at least two years.
Discussing Phase 2 results, Shankar said the medium dose showed about a 33% reduction in lesion growth when using the square root measure, while the company observed a bell-shaped dose-response pattern rather than a linear one. He said the high dose did not perform as consistently as the medium dose, leading Ocugen to select the medium dose for Phase 3.
For the pivotal study, Shankar said Ocugen plans to use a baseline lesion size range of 2.5 mm squared to 17.5 mm squared, consistent with approved products, and will measure the rate of change in lesion size at four-month intervals through 12 months. He said the company expects to enroll fewer than 300 patients and plans an adaptive design in which a data monitoring committee may review the trial after 50% of patients complete one year.
Shankar said Ocugen designed the trial assuming an effect size lower than the Phase 2 result, using roughly 25% to build in a buffer. Secondary endpoints will include ellipsoid zone preservation and low-luminance visual acuity. He said the medium dose showed about 27% preservation of ellipsoid zone loss in Phase 2, and the company hopes to see results in the 20%-plus range.
On safety, Shankar said there were no serious adverse events related to the drug in Phase 2, though some surgery-related issues can occur with vitrectomy and most resolved.
Stargardt Program OCU410ST Amin also asked about OCU410ST, Ocugen’s program for Stargardt disease. Shankar said Phase 1 results from the GARDian1 trial showed a 54% reduction in lesion growth in evaluable subjects compared with untreated eyes, using the contralateral eye as a control. He said the result informed the design of the Phase 2/3 pivotal study, which included 51 planned subjects, with 34 treated and 17 untreated.
Shankar said the company is also monitoring ellipsoid zone and low-luminance visual acuity as secondary measures. He said the program is intended as a one-time therapy and is being studied across a broad range of patients, including pediatric and adult patients aged three and older and patients from early to advanced stages of disease.
The GARDian3 pivotal trial includes an adaptive sample size re-estimation, which Shankar said is expected this quarter. He said the data monitoring committee could recommend no change, an adjustment in sample size or an extension of follow-up from 12 months to 16 months. Ocugen over-recruited the study to 63 patients, he said, potentially reducing the need for additional enrollment if the committee recommends a larger sample.
If no changes are made, Shankar said top-line results are expected in the second quarter of next year, followed by a BLA filing “a few weeks after that” or around mid-next year. If the timeline is extended, he said any delay could be roughly four to six months and still could allow the company to reach year-end next year. He also said no serious adverse events related to the drug have been observed so far in the Stargardt program.
OCU400 for Retinitis Pigmentosa Ocugen’s third program, OCU400, targets retinitis pigmentosa. Shankar said enrollment is complete in the Phase 3 trial, with top-line data expected in the first half of next year. He described the trial as a large genetic medicine study with 140 patients and more than 25 genetic mutations represented.
Shankar said OCU400 uses NR2E3 delivered through an AAV vector and is designed to be gene-agnostic by upregulating key transcription factors and helping reset cellular function. He said the trial includes a 2:1 randomization ratio, with more patients in the treatment arm than the control arm, and covers a broad population that includes syndromic and non-syndromic retinitis pigmentosa.
The primary functional assessment will use a Luminance Dependent Navigation Assessment, which Shankar said is similar to the multi-luminance mobility test used in the approval of Luxturna but modified to be more specific and sensitive. He said the trial will compare the rate of improvement over one year against the control arm.
Upcoming Milestones Shankar said Ocugen is aiming for two top-line readouts next year from its retinitis pigmentosa and Stargardt programs, followed by a third program readout in geographic atrophy in 2028. He reiterated the company’s goal of filing three BLAs over the next two years, followed by marketing authorization applications and potential global approvals.
“We’re going after with our one-time potential treatments, targeting hundreds of thousands to millions,” Shankar said, describing that as a key point of differentiation for the company.
About Ocugen NASDAQ: OCGNOcugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.
In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Ocugen Right Now?Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
In the latest trading session, T. Rowe Price (TROW - Free Report) closed at $118.55, marking a +1.28% move from the previous day. This move outpaced the S&P 500's daily gain of 0.42%. On the other hand, the Dow registered a gain of 0.29%, and the technology-centric Nasdaq increased by 0.29%.
Coming into today, shares of the financial services firm had gained 8.11% in the past month. In that same time, the Finance sector gained 4.33%, while the S&P 500 gained 2.2%.
Market participants will be closely following the financial results of T. Rowe Price in its upcoming release. The company plans to announce its earnings on July 31, 2026. In that report, analysts expect T. Rowe Price to post earnings of $2.37 per share. This would mark year-over-year growth of 5.8%. Meanwhile, the latest consensus estimate predicts the revenue to be $1.88 billion, indicating a 8.85% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $9.76 per share and revenue of $7.59 billion, which would represent changes of +0.41% and +3.73%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for T Rowe Price. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.4% higher within the past month. T. Rowe Price is currently a Zacks Rank #3 (Hold).
In the context of valuation, T. Rowe Price is at present trading with a Forward P/E ratio of 11.99. For comparison, its industry has an average Forward P/E of 11.67, which means T. Rowe Price is trading at a premium to the group.
It is also worth noting that TROW currently has a PEG ratio of 5.91. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Financial - Investment Management industry was having an average PEG ratio of 1.04.
The Financial - Investment Management industry is part of the Finance sector. Currently, this industry holds a Zacks Industry Rank of 181, positioning it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Lucid Group (LCID - Free Report) closed the most recent trading day at $5.55, moving -4.8% from the previous trading session. This change lagged the S&P 500's 0.42% gain on the day. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq gained 0.29%.
The an electric vehicle automaker's stock has climbed by 12.77% in the past month, exceeding the Auto-Tires-Trucks sector's gain of 0.6% and the S&P 500's gain of 2.2%.
The upcoming earnings release of Lucid Group will be of great interest to investors. The company's earnings report is expected on August 4, 2026. The company is predicted to post an EPS of -$2.58, indicating a 7.86% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $373.56 million, indicating a 43.99% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$11.12 per share and a revenue of $2.18 billion, signifying shifts of +8.02% and +60.83%, respectively, from the last year.
Any recent changes to analyst estimates for Lucid Group should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.39% lower within the past month. At present, Lucid Group boasts a Zacks Rank of #3 (Hold).
The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. This group has a Zacks Industry Rank of 43, putting it in the top 18% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow LCID in the coming trading sessions, be sure to utilize Zacks.com.
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.
So What: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Jefferies Financial Group, Inc. (“Jefferies” or the “Company”) (NYSE:JEF). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On June 25, 2026, Jefferies reported quarterly results showing weaker asset-management fees and investment returns driven in part by Jefferies’ asset-management unit, Point Bonita Capital. The Securities and Exchange Commission is reportedly investigation claims that Jefferies misled investors about the Company’s exposure to First Brands Group, a now-bankrupt auto-parts supplier, through Point Bonita. According to public reports, funds run by Point Bonita were owed roughly $715 million from companies that bought First Brands’ parts. First Brands filed for bankruptcy in September 2025 amid accounting questions, and Jefferies later disclosed a $30 million loss tied to the collapse. On this news, the price of Jefferies shares declined by $5.30 per share, or approximately 9%, from $57.94 per share on June 24, 2026 to close at $52.64 on June 25, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Jefferies securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
In the latest trading session, Rocket Lab Corporation (RKLB - Free Report) closed at $81.04, marking a -1.83% move from the previous day. This move lagged the S&P 500's daily gain of 0.42%. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq gained 0.29%.
Shares of the company have depreciated by 28.08% over the course of the past month, underperforming the Aerospace sector's gain of 1.11%, and the S&P 500's gain of 2.2%.
Analysts and investors alike will be keeping a close eye on the performance of Rocket Lab Corporation in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.03, reflecting a 70% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $232.88 million, up 61.16% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.09 per share and revenue of $925.92 million. These totals would mark changes of +66.67% and +53.86%, respectively, from last year.
Any recent changes to analyst estimates for Rocket Lab Corporation should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 9.3% increase. Rocket Lab Corporation presently features a Zacks Rank of #3 (Hold).
The Aerospace - Defense Equipment industry is part of the Aerospace sector. This industry, currently bearing a Zacks Industry Rank of 53, finds itself in the top 22% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Dynatrace (DT - Free Report) ended the recent trading session at $43.68, demonstrating a -3.43% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.42%. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq gained 0.29%.
The software intellegence company's stock has climbed by 12.04% in the past month, exceeding the Computer and Technology sector's gain of 0.85% and the S&P 500's gain of 2.2%.
The upcoming earnings release of Dynatrace will be of great interest to investors. The company's earnings per share (EPS) are projected to be $0.45, reflecting a 7.14% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $549.3 million, reflecting a 15.07% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $1.95 per share and a revenue of $2.33 billion, demonstrating changes of +14.71% and +15.23%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Dynatrace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Dynatrace presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Dynatrace is currently trading at a Forward P/E ratio of 23.24. This represents a premium compared to its industry average Forward P/E of 13.05.
It's also important to note that DT currently trades at a PEG ratio of 1.67. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Computers - IT Services was holding an average PEG ratio of 1.02 at yesterday's closing price.
The Computers - IT Services industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 102, positioning it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
In the latest trading session, Paccar (PCAR - Free Report) closed at $124.57, marking a +1.05% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.42% for the day. On the other hand, the Dow registered a gain of 0.29%, and the technology-centric Nasdaq increased by 0.29%.
Prior to today's trading, shares of the truck maker had gained 4.85% outpaced the Auto-Tires-Trucks sector's gain of 0.6% and the S&P 500's gain of 2.2%.
The investment community will be closely monitoring the performance of Paccar in its forthcoming earnings report. The company is scheduled to release its earnings on July 28, 2026. The company is predicted to post an EPS of $1.32, indicating a 3.65% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.1 billion, up 1.92% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $5.58 per share and a revenue of $27.7 billion, demonstrating changes of +11.38% and +5.59%, respectively, from the preceding year.
Any recent changes to analyst estimates for Paccar should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.15% lower within the past month. Paccar presently features a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Paccar has a Forward P/E ratio of 22.09 right now. This represents a premium compared to its industry average Forward P/E of 18.19.
It's also important to note that PCAR currently trades at a PEG ratio of 1.15. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Automotive - Domestic industry had an average PEG ratio of 1.
The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. At present, this industry carries a Zacks Industry Rank of 43, placing it within the top 18% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PCAR in the coming trading sessions, be sure to utilize Zacks.com.
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ:HUBG) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
If you suffered a loss on your Hub Group investments, you have until August 28, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.
Follow the link below for more information about the lawsuit:
[CONTACT THE FIRM IF YOU SUFFERED A LOSS]
What Is The Lawsuit About?
The lawsuit has been filed on behalf of investors who purchased securities during the period of April 28, 2023 through May 11, 2026, inclusive (“the Class Period”). The complaint alleges that the Company made materially false and misleading statements including financial statements that were materially inaccurate due to premature revenue recognition and the understatement of purchased transportation costs and accounts payable, as well as statements concerning the effectiveness of internal controls, and the Company’s drivers of financial results and growth.
On February 5, 2026, Hub Group announced that the Company’s financial statements for the first three quarters of 2025 should not be relied upon and would be restated due to “an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025.” The Company revealed that its reports for those quarters “were in each case materially misstated due to the aforementioned error and should no longer be relied upon” and that “the Company [wa]s also continuing to assess the effectiveness of its disclosure controls and procedures and internal control over financial reporting and appropriate remediation steps.” The Company also estimated that “[t]he total amount of the reduction to accounts payable and purchased transportation costs related to this issue that was recorded during these periods is $77 million.” On this news, the price of Hub Group shares declined by $9.37 per share, or approximately 18%, from $51.33 per share on February 5, 2026 to close at $41.96 on February 26, 2026.
On May 12, 2026, Hub Group announced that it had “identified certain transactions that were prematurely or incorrectly recognized or not adequately supported,” causing its 2023 and 2024 annual reports filed with the SEC to be “materially misstated,” such that they “should no longer be relied upon.” The Company did not quantify the expected misstatement, although it “expect[ed] to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023.” On this news, the price of Hub Group shares declined by $5.24 per share, or approximately 13%, from $41.86 per share on May 11, 2026 to close at $36.62 on May 12, 2026.
[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]
What Should I Do?
If you purchased or otherwise acquired Hub Group securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[HOW CAN I PROTECT MY RIGHTS?]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of purchasers of securities of Hub Group, Inc. (NASDAQ: HUBG) between April 28, 2023 and May 11, 2026, inclusive (the "Class Period"), of the important August 28, 2026 lead plaintiff deadline.
So what: If you purchased Hub Group securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that Hub Group's financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements—caused by the premature and incorrect recognition of certain transactions—concerning, inter alia, Hub Group's operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth. In addition, Hub Group's financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements—caused by the understatement of purchased transportation costs and accounts payable —concerning, inter alia, Hub Group's operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SAN DIEGO, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of United States federal securities laws involving The Ensign Group, Inc. (NASDAQ: ENSG).
If you any have information that could assist in the Ensign investigation or if you are an Ensign investor who suffered a loss and would like to learn more, you may provide your information here:
You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
THE COMPANY: Ensign provides skilled nursing, senior living, and rehabilitative services.
THE REVELATION: On June 11, 2026, Muddy Waters Research published a report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities: Multi-Billion Dollar Potential Liability, Margins and Acquisitions that Cannot be Sustained Without Significant Ongoing Misconduct.” On this news, the price of Ensign stock fell.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.
Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
Ken Dolitsky
Michael Albert
655 W. Broadway, Suite 1900, San Diego, CA 92101
800/851-7783 [email protected]
The publication countersued the Equal Employment Opportunity Commission, alleging a discrimination suit it filed on behalf of white, male editor is unlawful
In the latest trading session, IonQ, Inc. (IONQ - Free Report) closed at $42.86, marking a -4.27% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.42%. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq appreciated by 0.29%.
The stock of company has fallen by 22.8% in the past month, lagging the Computer and Technology sector's gain of 0.85% and the S&P 500's gain of 2.2%.
Investors will be eagerly watching for the performance of IonQ, Inc. in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.29, reflecting a 58.57% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $66.36 million, indicating a 220.73% upward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.07 per share and revenue of $267.45 million. These totals would mark changes of +41.21% and +105.71%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for IonQ, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. IonQ, Inc. presently features a Zacks Rank of #3 (Hold).
The Computer - Integrated Systems industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 4, placing it within the top 2% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Alaska Air Group (ALK - Free Report) closed the most recent trading day at $49.42, moving -1.44% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.42%. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq gained 0.29%.
Heading into today, shares of the airline had gained 7.46% over the past month, outpacing the Transportation sector's gain of 0.73% and the S&P 500's gain of 2.2%.
Analysts and investors alike will be keeping a close eye on the performance of Alaska Air Group in its upcoming earnings disclosure. The company's earnings report is set to go public on July 21, 2026. In that report, analysts expect Alaska Air Group to post earnings of -$0.97 per share. This would mark a year-over-year decline of 154.49%. Meanwhile, the latest consensus estimate predicts the revenue to be $4.09 billion, indicating a 10.55% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.25 per share and a revenue of $15.85 billion, indicating changes of -110.25% and +11.32%, respectively, from the former year.
Any recent changes to analyst estimates for Alaska Air Group should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 75.05% higher. Alaska Air Group is currently a Zacks Rank #3 (Hold).
The Transportation - Airline industry is part of the Transportation sector. This industry, currently bearing a Zacks Industry Rank of 173, finds itself in the bottom 30% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ALK in the coming trading sessions, be sure to utilize Zacks.com.
On July 10, 2026, Advance Auto Parts Inc (AAP) shares rose 5.4% to $57.95. Despite today's positive movement, the stock has experienced a decline of 5.4% over t
On July 10, 2026, Freshpet Inc (FRPT) shares experienced a decline of 3.3%, now trading at $53.62. This drop continues a trend, as the stock has fallen 12.0% ye
Freshpet (FRPT - Free Report) closed at $53.62 in the latest trading session, marking a -3.34% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.42% for the day. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 0.29%.
The seller of refrigerated fresh pet food's stock has climbed by 6.22% in the past month, exceeding the Consumer Staples sector's gain of 0.59% and the S&P 500's gain of 2.2%.
The investment community will be closely monitoring the performance of Freshpet in its forthcoming earnings report. The company is expected to report EPS of $0.21, down 36.36% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $292.7 million, indicating a 10.58% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.76 per share and a revenue of $1.21 billion, indicating changes of -33.33% and +9.52%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Freshpet. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Freshpet is carrying a Zacks Rank of #3 (Hold).
From a valuation perspective, Freshpet is currently exchanging hands at a Forward P/E ratio of 31.61. Its industry sports an average Forward P/E of 13.02, so one might conclude that Freshpet is trading at a premium comparatively.
The Food - Miscellaneous industry is part of the Consumer Staples sector. With its current Zacks Industry Rank of 200, this industry ranks in the bottom 19% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Vancouver, British Columbia--(Newsfile Corp. - July 10, 2026) - Carlyle Commodities Corp. (CSE: CCC) (OTC: CCCFF) (FSE: BJ4) ("Carlyle" or the "Company") is pleased to announce that it has received conditional approval of the Canadian Securities Exchange (the "CSE") for its previously announced proposed transaction (the "Transaction") with Silver Pony Resources Corp. ("SPR"), pursuant to which the Company will acquire all of the issued and outstanding shares of SPR by way of a three-cornered amalgamation in accordance with Section 269 of the Business Corporations Act (British Columbia), as further described in the Company's news releases dated March 31, 2026 and June 10, 2026. The Transaction will constitute a "Fundamental Change" of the Company as defined by the policies of the CSE.
The Company also announces that it has obtained requisite shareholder approval for the Transaction by written consent in accordance with Section 4.6(1) of CSE Policy 4.
Completion of the Transaction remains subject to the final approval of the CSE, and the satisfaction of other customary closing conditions as set out in the amalgamation agreement dated March 30, 2026, among the Company, SPR and 1582613 B.C. Ltd.
About Carlyle Commodities Corp.
The Company is a mineral exploration company focused on the acquisition, exploration, and development of mineral resource properties. Carlyle owns 100% of the Quesnel Gold Project located in the Cariboo Mining Division, 30 kilometers northeast of Quesnel in central B.C., and holds the option to acquire 100% undivided interest in the Nicola East Mining Project, located approximately 25 kilometers east of the mining town of Merritt, B.C., and is listed on the CSE under the symbol "CCC" and the Frankfurt Exchange under the ticker "BJ4".
For more information, please contact the Company at:
Carlyle Commodities Corp.
Forward Looking Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of Carlyle regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts; statements as to management's expectations and intentions with respect to, among other things, the expected closing of the Transaction and the receipt of final CSE approval.
These forward-looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company may not complete the Transaction on the anticipated timeline or at all; the Company may not receive all required regulatory approvals, including final approval of the CSE; the conditions precedent to completion of the Transaction may not be satisfied or waived;; and other risks and uncertainties disclosed in the Company's public disclosure record available under the Company's profile on SEDAR+ at www.sedarplus.ca.
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: the Company will obtain all necessary regulatory approvals, including final approval of the CSE; all conditions precedent to completion of the Transaction will be satisfied or waived in accordance with the terms of the amalgamation agreement; and the Transaction will be completed substantially on the terms and within the timeframe currently anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304845
Source: Carlyle Commodities Corp.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
In the latest trading session, Marvell Technology (MRVL - Free Report) closed at $235.81, marking a -3.07% move from the previous day. This move lagged the S&P 500's daily gain of 0.42%. On the other hand, the Dow registered a gain of 0.29%, and the technology-centric Nasdaq increased by 0.29%.
Shares of the chipmaker have depreciated by 13.34% over the course of the past month, underperforming the Computer and Technology sector's gain of 0.85%, and the S&P 500's gain of 2.2%.
The investment community will be paying close attention to the earnings performance of Marvell Technology in its upcoming release. The company is forecasted to report an EPS of $0.93, showcasing a 38.81% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.71 billion, up 35.1% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.04 per share and a revenue of $11.54 billion, indicating changes of +42.25% and +40.88%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Marvell Technology. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.22% decrease. Marvell Technology is holding a Zacks Rank of #3 (Hold) right now.
Looking at valuation, Marvell Technology is presently trading at a Forward P/E ratio of 60.16. For comparison, its industry has an average Forward P/E of 49.7, which means Marvell Technology is trading at a premium to the group.
It's also important to note that MRVL currently trades at a PEG ratio of 1.21. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Electronics - Semiconductors industry had an average PEG ratio of 1.89.
The Electronics - Semiconductors industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 42, placing it within the top 18% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
In the latest close session, Copart, Inc. (CPRT - Free Report) was down 2.88% at $27.52. This change lagged the S&P 500's 0.42% gain on the day. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq appreciated by 0.29%.
The company's shares have seen a decrease of 8.79% over the last month, not keeping up with the Business Services sector's gain of 2.8% and the S&P 500's gain of 2.2%.
Market participants will be closely following the financial results of Copart, Inc. in its upcoming release. On that day, Copart, Inc. is projected to report earnings of $0.39 per share, which would represent a year-over-year decline of 4.88%. Meanwhile, our latest consensus estimate is calling for revenue of $1.14 billion, up 1.23% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.58 per share and revenue of $4.63 billion, indicating changes of -0.63% and -0.37%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Copart, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% lower. Currently, Copart, Inc. is carrying a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Copart, Inc. has a Forward P/E ratio of 17.91 right now. This expresses a discount compared to the average Forward P/E of 26.25 of its industry.
The Auction and Valuation Services industry is part of the Business Services sector. This group has a Zacks Industry Rank of 236, putting it in the bottom 5% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Lululemon (LULU - Free Report) closed at $119.26 in the latest trading session, marking a +2.36% move from the prior day. This change outpaced the S&P 500's 0.42% gain on the day. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq appreciated by 0.29%.
Prior to today's trading, shares of the athletic apparel maker had lost 4.37% lagged the Consumer Discretionary sector's gain of 0.02% and the S&P 500's gain of 2.2%.
Investors will be eagerly watching for the performance of Lululemon in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.79, marking a 42.26% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $2.47 billion, reflecting a 2.26% fall from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.08 per share and a revenue of $11.08 billion, signifying shifts of -16.44% and -0.22%, respectively, from the last year.
Any recent changes to analyst estimates for Lululemon should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.51% lower. Currently, Lululemon is carrying a Zacks Rank of #5 (Strong Sell).
From a valuation perspective, Lululemon is currently exchanging hands at a Forward P/E ratio of 10.52. This expresses a discount compared to the average Forward P/E of 15.73 of its industry.
Also, we should mention that LULU has a PEG ratio of 3.77. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Textile - Apparel industry stood at 2.14 at the close of the market yesterday.
The Textile - Apparel industry is part of the Consumer Discretionary sector. At present, this industry carries a Zacks Industry Rank of 191, placing it within the bottom 23% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Builders FirstSource (BLDR - Free Report) ended the recent trading session at $75.69, demonstrating a +1.54% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.42%. Meanwhile, the Dow experienced a rise of 0.29%, and the technology-dominated Nasdaq saw an increase of 0.29%.
Prior to today's trading, shares of the construction supply company had lost 5.13% lagged the Retail-Wholesale sector's gain of 0.24% and the S&P 500's gain of 2.2%.
The investment community will be paying close attention to the earnings performance of Builders FirstSource in its upcoming release. The company is slated to reveal its earnings on July 30, 2026. The company is predicted to post an EPS of $1.32, indicating a 44.54% decline compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $3.93 billion, indicating a 7.22% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $4.32 per share and revenue of $14.87 billion, which would represent changes of -37.3% and -2.08%, respectively, from the prior year.
Any recent changes to analyst estimates for Builders FirstSource should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.19% increase. Builders FirstSource is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Builders FirstSource's current valuation metrics, including its Forward P/E ratio of 17.27. This represents a discount compared to its industry average Forward P/E of 17.28.
Also, we should mention that BLDR has a PEG ratio of 1.77. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Building Products - Retail was holding an average PEG ratio of 1.77 at yesterday's closing price.
The Building Products - Retail industry is part of the Retail-Wholesale sector. At present, this industry carries a Zacks Industry Rank of 204, placing it within the bottom 18% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
BellRing Brands (BRBR - Free Report) ended the recent trading session at $12.48, demonstrating a +2.72% change from the preceding day's closing price. This change outpaced the S&P 500's 0.42% gain on the day. On the other hand, the Dow registered a gain of 0.29%, and the technology-centric Nasdaq increased by 0.29%.
Coming into today, shares of the nutritional supplements company had gained 36.36% in the past month. In that same time, the Consumer Staples sector gained 0.59%, while the S&P 500 gained 2.2%.
Analysts and investors alike will be keeping a close eye on the performance of BellRing Brands in its upcoming earnings disclosure. The company's earnings report is set to go public on August 4, 2026. It is anticipated that the company will report an EPS of $0.36, marking a 34.55% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $553.26 million, reflecting a 1.05% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $1.22 per share and revenue of $2.33 billion. These totals would mark changes of -43.78% and +0.7%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for BellRing Brands. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.37% lower. BellRing Brands is currently a Zacks Rank #3 (Hold).
Looking at its valuation, BellRing Brands is holding a Forward P/E ratio of 9.93. For comparison, its industry has an average Forward P/E of 13.02, which means BellRing Brands is trading at a discount to the group.
We can also see that BRBR currently has a PEG ratio of 5.98. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Food - Miscellaneous industry stood at 2.44 at the close of the market yesterday.
The Food - Miscellaneous industry is part of the Consumer Staples sector. This industry currently has a Zacks Industry Rank of 200, which puts it in the bottom 19% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $53.35, moving -5.31% from the previous trading session. This change lagged the S&P 500's 0.42% gain on the day. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 0.29%.
Shares of the company have appreciated by 12.16% over the course of the past month, outperforming the Medical sector's gain of 5.6%, and the S&P 500's gain of 2.2%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.12 per share. This would mark year-over-year growth of 13.18%. Our most recent consensus estimate is calling for quarterly revenue of $7.42 million, up 733.26% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.89 per share and revenue of $28.88 million. These totals would mark changes of +24.42% and +722.82%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.22% increase. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 106, this industry ranks in the top 44% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
In the latest close session, Quanta Services (PWR - Free Report) was down 1.44% at $658.56. The stock's performance was behind the S&P 500's daily gain of 0.42%. Meanwhile, the Dow gained 0.29%, and the Nasdaq, a tech-heavy index, added 0.29%.
Shares of the specialty contractor for utility and energy companies have depreciated by 2.21% over the course of the past month, underperforming the Construction sector's loss of 1.68%, and the S&P 500's gain of 2.2%.
Market participants will be closely following the financial results of Quanta Services in its upcoming release. It is anticipated that the company will report an EPS of $3.29, marking a 32.66% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $8.53 billion, reflecting a 25.87% rise from the equivalent quarter last year.
PWR's full-year Zacks Consensus Estimates are calling for earnings of $14.03 per share and revenue of $34.76 billion. These results would represent year-over-year changes of +30.51% and +22.03%, respectively.
Any recent changes to analyst estimates for Quanta Services should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Quanta Services is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Quanta Services is holding a Forward P/E ratio of 47.63. For comparison, its industry has an average Forward P/E of 24.64, which means Quanta Services is trading at a premium to the group.
Also, we should mention that PWR has a PEG ratio of 2.4. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Engineering - R and D Services was holding an average PEG ratio of 1.59 at yesterday's closing price.
The Engineering - R and D Services industry is part of the Construction sector. Currently, this industry holds a Zacks Industry Rank of 68, positioning it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PWR in the coming trading sessions, be sure to utilize Zacks.com.
In the latest trading session, MongoDB (MDB - Free Report) closed at $342.08, marking a -5.73% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.42%. Meanwhile, the Dow experienced a rise of 0.29%, and the technology-dominated Nasdaq saw an increase of 0.29%.
The stock of database platform has risen by 2.39% in the past month, leading the Computer and Technology sector's gain of 0.85% and the S&P 500's gain of 2.2%.
Analysts and investors alike will be keeping a close eye on the performance of MongoDB in its upcoming earnings disclosure. In that report, analysts expect MongoDB to post earnings of $1.6 per share. This would mark year-over-year growth of 60%. Meanwhile, our latest consensus estimate is calling for revenue of $733.61 million, up 24.05% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $6.07 per share and a revenue of $2.94 billion, indicating changes of +22.13% and +19.26%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for MongoDB. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. MongoDB is currently sporting a Zacks Rank of #3 (Hold).
From a valuation perspective, MongoDB is currently exchanging hands at a Forward P/E ratio of 59.76. For comparison, its industry has an average Forward P/E of 19.73, which means MongoDB is trading at a premium to the group.
Also, we should mention that MDB has a PEG ratio of 4.9. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Internet - Software was holding an average PEG ratio of 1.06 at yesterday's closing price.
The Internet - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
On July 10, 2026, Teradata Corp TDC shares fell 3.1% to a current price of $33.74. This price is situated within a 52-week range of $19.83 to $41.78, indicating significant volatility over the past year.
GF Value™ verdict: The current price is $33.74, while the GF Value™ estimate is $30.54, indicating the stock is 10.5% overvalued.GF Score™: TDC has a GF Score™ of 74/100, which is classified as above average.Most notable signal: Insiders sold $3.6 million worth of shares in the last three months, with no purchases reported. Is TDC Overvalued or Undervalued? Teradata's current price of $33.74 exceeds the GF Value™ estimate of $30.54, suggesting that the stock is overvalued by approximately 10.5%. This overvaluation raises concerns about the potential risks associated with investing at this price point, particularly in light of the recent insider selling activity. The GF Valuation label classifies the stock as fairly valued, but the current price significantly diverges from the intrinsic value indicated by GF Value™. A margin of safety is not present for potential investors, which may lead to reconsideration of any positions in the stock.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Investors should be cautious when considering the stock at this price, as the risk of a pullback could be substantial if earnings do not meet market expectations.
How Does TDC's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 7.7x 43.9x Forward P/E 12.7x N/A The current P/E (TTM) of 7.7x is significantly below its 5-year median P/E of 43.9x, indicating that the stock is trading at a much lower valuation compared to its historical averages. However, the forward P/E of 12.7x suggests some expected growth in earnings, but this remains to be seen. The P/E analysis aligns with the GF Value™ verdict of overvaluation, as the current trading multiples indicate a significant disconnect from historical valuation levels.
What Does TDC's GF Score™ Tell Us? Metric Rating GF Score™ 74/100 Financial Strength 6/10 Profitability 7/10 Growth 3/10 Valuation 6/10 Momentum 9/10 TDC's GF Score™ of 74/100 indicates a relatively strong position overall, particularly in the momentum category where it received a high score of 9/10. This suggests positive recent price performance, supporting the stock's short-term appeal. However, the growth rank of 3/10 is concerning, indicating potential challenges in achieving sustainable long-term growth. The financial strength and profitability ranks of 6/10 and 7/10, respectively, indicate stability and effective management but highlight a need for improvement in growth metrics.
What Are Insiders Doing with TDC Stock? Recent insider activity at Teradata has shown a trend of selling, with insiders offloading $3.6 million worth of shares over the last three months and no reported purchases. This pattern of selling may signal a lack of confidence from those within the company regarding its future performance or current valuation. Insider selling can often indicate that insiders believe the stock is overvalued or that they want to realize gains. Without any buying activity to counterbalance these sales, it raises concerns for potential investors.
What This Means for Investors Based on the GF Value™ assessment, Teradata Corp TDC is currently overvalued, with a current price higher than its estimated fair value. This valuation, combined with recent insider selling and lower growth scores, suggests caution for those considering investment in TDC at this time.
For the complete analysis, visit the Teradata Corp TDC stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is TDC's GF Score™?
TDC has a GF Score™ of 74/100, indicating an above-average potential for long-term returns based on key financial metrics.
Is TDC overvalued or undervalued?
According to the GF Value™ verdict, TDC is overvalued, as the current price of $33.74 exceeds the estimated fair value of $30.54.
What is TDC's P/E ratio?
TDC has a P/E (TTM) of 7.7x, which is significantly below its 5-year median of 43.9x, indicating that the stock is trading at a much lower valuation compared to its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
If you drive for Uber (NYSE:UBER | UBER Price Prediction), deliver for DoorDash (NASDAQ:DASH), or shop for Instacart (NASDAQ:CART), you almost certainly get a 1099-NEC at year-end and no benefits package. That is exactly why the IRS treats you as both the employer and the employee of your own one-person business, and why a Solo 401(k) lets you shovel far more into retirement than any W-2 coworker with a corporate plan. The combined limit for 2026 (verify the current figure at IRS.gov before you fund) is the ceiling almost no rideshare or delivery driver actually uses.
Why Gig Drivers Are Actually Self-Employed Business Owners Uber, Lyft (NASDAQ:LYFT), DoorDash, Instacart, and Grubhub classify drivers as independent contractors. That means no employer 401(k) match, no payroll tax split, and the full 15.3% self-employment tax lands on you. The upside: the IRS lets sole proprietors open a Solo 401(k), a plan built for owner-only businesses with no employees other than a spouse.
The plan has two contribution buckets, and you fill both:
Employee deferral: up to the standard 401(k) elective limit ($23,000 in 2024, indexed higher for 2026; verify the current figure). Employer profit-sharing: roughly 20% of net self-employment earnings, stacked on top of the deferral. Combined, those two buckets are what push the ceiling into the range the headline names. If you are 50 or older, a catch-up contribution goes on top of that.
The Math a Full-Time Rideshare Driver Can Actually Hit You do not need six figures of profit to make this meaningful. Say a full-time driver nets $55,000 after mileage deductions. The employee bucket alone lets that driver defer most of a year’s savings capacity, and the profit-sharing side layers on roughly another 20% of net earnings. Even a part-time weekend driver netting $12,000 can route the entire amount into the employee bucket, because there is no minimum.
Context matters here. The U.S. personal savings rate sat at 3.9% in Q1 2026, down from 6.2% in Q1 2024, and personal consumption absorbed 92.3% of disposable income. Gig income is lumpy on top of that. The Solo 401(k) fits because you can fund it in bursts, not on a payroll schedule, and you have until your tax filing deadline (plus extensions for the employer portion) to make the prior-year contribution.
Roth or Traditional, Your Choice, on Both Sides Most low-cost providers now offer a Roth Solo 401(k). As one financial commentator put it, the solo 401(k) “gives you more of the flexibility of contribution limits significantly beyond what you can do just in a Roth” IRA. Under recent rule changes, employer profit-sharing contributions can also be designated Roth. If you expect higher tax rates later, or you are in a low bracket now because of heavy mileage deductions, the Roth side is worth serious consideration.
SEP-IRA vs. Solo 401(k) The SEP-IRA is simpler and better known, and it is what most CPAs default to for gig workers. But it only has the employer bucket, capped near 20% of net earnings. A driver clearing $40,000 can put far more into a Solo 401(k) than a SEP because the employee deferral bucket does not depend on profit. The SEP also complicates any future backdoor Roth IRA because of pro-rata rules. The Solo 401(k) avoids that trap.
Why Almost Nobody Uses It Awareness: platforms do not tell drivers they qualify. Compare that to W-2 workers, where Vanguard’s plan-weighted 401(k) participation rate hit 85% in 2024, largely because of auto-enrollment. Paperwork friction: you need an EIN and a plan document. Fidelity, Schwab (NYSE:SCHW), and E*TRADE offer no-fee Solo 401(k)s, but you have to open them yourself. Cash flow: average annual household expenditures reached $78,535 in 2024, and median full-time weekly earnings ran $1,235 in Q1 2026. Gig income often lands below that median, so “save it later” wins. Form 5500-EZ: once plan assets exceed $250,000, you owe an annual filing. Skippable at first, but real. The Move Get an EIN from IRS.gov (free, five minutes). Open a Solo 401(k) with a no-fee brokerage. Fund the employee bucket first because it is not profit-limited, then add profit-sharing when you file.
Contact [email protected] for any questions or corrections.
Cipher Digital Inc. (CIFR - Free Report) closed at $22.11 in the latest trading session, marking a -4.94% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.42%. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 0.29%.
Shares of the company witnessed a gain of 2.78% over the previous month, trailing the performance of the Business Services sector with its gain of 2.8%, and outperforming the S&P 500's gain of 2.2%.
Investors will be eagerly watching for the performance of Cipher Digital Inc. in its upcoming earnings disclosure. In that report, analysts expect Cipher Digital Inc. to post earnings of -$0.24 per share. This would mark a year-over-year decline of 100%. Our most recent consensus estimate is calling for quarterly revenue of $29.79 million, down 31.62% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.8 per share and a revenue of $232.16 million, indicating changes of +62.79% and +3.67%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Cipher Digital Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Cipher Digital Inc. is currently a Zacks Rank #3 (Hold).
The Technology Services industry is part of the Business Services sector. This group has a Zacks Industry Rank of 152, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
On July 10, 2026, WD-40 Co (WDFC) shares rose by 10.7% to a current price of $264.91. This increase comes as part of a strong performance trend, with the shares
Tenet Healthcare (THC - Free Report) closed the most recent trading day at $204.25, moving -1.22% from the previous trading session. This change lagged the S&P 500's 0.42% gain on the day. Meanwhile, the Dow experienced a rise of 0.29%, and the technology-dominated Nasdaq saw an increase of 0.29%.
Prior to today's trading, shares of the hospital operator had gained 19.4% outpaced the Medical sector's gain of 5.6% and the S&P 500's gain of 2.2%.
Investors will be eagerly watching for the performance of Tenet Healthcare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 24, 2026. The company's upcoming EPS is projected at $4.08, signifying a 1.49% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.39 billion, up 2.27% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.61 per share and a revenue of $22.02 billion, indicating changes of +4.95% and +3.32%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Tenet Healthcare. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Tenet Healthcare is holding a Zacks Rank of #2 (Buy) right now.
With respect to valuation, Tenet Healthcare is currently being traded at a Forward P/E ratio of 11.74. This expresses no noticeable deviation compared to the average Forward P/E of 11.74 of its industry.
It is also worth noting that THC currently has a PEG ratio of 1.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Hospital industry had an average PEG ratio of 1.7 as trading concluded yesterday.
The Medical - Hospital industry is part of the Medical sector. With its current Zacks Industry Rank of 60, this industry ranks in the top 25% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
In the latest trading session, Equinix (EQIX - Free Report) closed at $1,051.21, marking a +1.58% move from the previous day. This move outpaced the S&P 500's daily gain of 0.42%. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq appreciated by 0.29%.
The data center operator's stock has dropped by 0.8% in the past month, falling short of the Finance sector's gain of 4.33% and the S&P 500's gain of 2.2%.
The upcoming earnings release of Equinix will be of great interest to investors. The company's earnings report is expected on July 29, 2026. It is anticipated that the company will report an EPS of $11.25, marking a 13.52% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $2.59 billion, indicating a 14.82% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $43.05 per share and a revenue of $10.24 billion, indicating changes of +12.31% and +11.05%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Equinix. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Equinix holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Equinix has a Forward P/E ratio of 24.04 right now. This expresses a premium compared to the average Forward P/E of 15.29 of its industry.
We can also see that EQIX currently has a PEG ratio of 1.71. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the REIT and Equity Trust - Retail industry stood at 2.56 at the close of the market yesterday.
The REIT and Equity Trust - Retail industry is part of the Finance sector. This group has a Zacks Industry Rank of 102, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
On July 10, 2026, Whirlpool Corp (WHR) shares rose 7.5% today, currently trading at $40.72. The stock has experienced significant volatility, with a 52-week ran
New community in the heart of Silicon Valley and within walking distance of highly rated schools and local parks is now open for tours.
, /PRNewswire/ -- KB Home (NYSE: KBH), one of the largest and most trusted homebuilders in the U.S., today announced the opening of Meadowbrook, which offers a rare opportunity to own a new townhome in Campbell, California.
Meadowbrook at a Glance:
KB Home, one of the largest and most trusted homebuilders in the U.S., today announced the opening of Meadowbrook, which offers a rare opportunity to own a new townhome in Campbell, California. Price: From $1.2M Location: Campbell, California, on Virginia Avenue just south of West Campbell Avenue and near San Tomas Expressway Home type: Three-story townhomes Bedrooms/baths: Up to 4 bedrooms and 3.5 baths School districts: Campbell Union School District and Campbell Union High School District Amenities: Park and playground Meadowbrook is in a central location that provides convenient access to San Tomas Expressway, Highway 17 and Highway 85, which connect residents to Silicon Valley's major employers and San Jose Mineta International Airport. The community is a short drive to Santana Row and minutes away from downtown Campbell and The Pruneyard Shopping Center for shopping, dining and entertainment. Meadowbrook is also close to art galleries and museums, including Ainsley House. Homeowners will appreciate the proximity to outdoor recreation at Los Gatos Creek Trail and Lexington and Stevens Creek Reservoirs.
The homes at Meadowbrook are designed for contemporary living, with modern kitchens overlooking large great rooms, expansive bedroom suites with walk-in closets, and ample storage space. Homebuyers can personalize their new home at the KB Home Design Studio, where they can select from a wide range of interior design choices that fit their style and budget.
"With Meadowbrook, we're bringing beautiful new townhomes to Campbell, a highly desirable city in Silicon Valley. The new community is within walking distance of highly ranked schools and John D. Morgan Park," said Oren Hershkovich, Regional General Manager of KB Home Northern California. "At KB Home, we focus on creating value through competitive, transparent pricing and giving buyers the ability to personalize their home based on what matters most to them. We put them in control, so they're not paying for features they don't value or compromising on ones they do."
KB homes are engineered to be highly energy and water efficient and include features that support healthier indoor environments. They are designed to be ENERGY STAR® certified, a standard that fewer than 12% of new homes nationwide meet, offering greater comfort, well-being and utility cost savings compared to new homes without certification.
The Meadowbrook sales office and model homes are now open for walk-in visits and private in-person tours by appointment. Live video tours are also available. For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.
About KB Home
KB Home is one of the largest and most trusted homebuilders in the U.S. We operate in 50 markets, have built over 700,000 quality homes in our nearly 70-year history, and are honored to be one of the top customer-ranked national homebuilders based on third-party buyer surveys. What sets KB Home apart is building strong, personal relationships with every customer and creating an exceptional experience that offers our homebuyers the ability to personalize their home based on what they value at a price they can afford. As the industry leader in sustainability, KB Home has achieved one of the highest residential energy-efficiency ratings and delivered more ENERGY STAR® certified homes than any other builder, helping to lower the total cost of homeownership. For more information, visit kbhome.com.
For Further Information:
Craig LeMessurier, KB Home
925-580-1583
[email protected]
Howmet (HWM - Free Report) closed at $270.85 in the latest trading session, marking a -1.07% move from the prior day. This move lagged the S&P 500's daily gain of 0.42%. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq gained 0.29%.
The maker of engineered products for the aerospace and other industries's shares have seen an increase of 3.47% over the last month, surpassing the Aerospace sector's gain of 1.11% and the S&P 500's gain of 2.2%.
Market participants will be closely following the financial results of Howmet in its upcoming release. The company plans to announce its earnings on August 6, 2026. The company's upcoming EPS is projected at $1.24, signifying a 36.26% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $2.42 billion, up 17.68% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $4.98 per share and revenue of $9.74 billion, which would represent changes of +32.1% and +18.02%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Howmet. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.11% rise in the Zacks Consensus EPS estimate. Howmet is holding a Zacks Rank of #2 (Buy) right now.
Looking at valuation, Howmet is presently trading at a Forward P/E ratio of 54.99. This valuation marks a premium compared to its industry average Forward P/E of 22.59.
It is also worth noting that HWM currently has a PEG ratio of 2.18. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Aerospace - Defense industry stood at 1.58 at the close of the market yesterday.
The Aerospace - Defense industry is part of the Aerospace sector. With its current Zacks Industry Rank of 102, this industry ranks in the top 42% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
In the latest close session, Wingstop (WING - Free Report) was down 2.81% at $153.29. This change lagged the S&P 500's 0.42% gain on the day. On the other hand, the Dow registered a gain of 0.29%, and the technology-centric Nasdaq increased by 0.29%.
Coming into today, shares of the restaurant chain had gained 2.5% in the past month. In that same time, the Retail-Wholesale sector gained 0.24%, while the S&P 500 gained 2.2%.
The investment community will be paying close attention to the earnings performance of Wingstop in its upcoming release. The company is slated to reveal its earnings on July 29, 2026. It is anticipated that the company will report an EPS of $1.02, marking a 2% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $190.27 million, reflecting a 9.14% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.57 per share and a revenue of $776.14 million, indicating changes of +12.01% and +11.38%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Wingstop. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.49% fall in the Zacks Consensus EPS estimate. Currently, Wingstop is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Wingstop is presently trading at a Forward P/E ratio of 34.52. This denotes a premium relative to the industry average Forward P/E of 19.93.
It's also important to note that WING currently trades at a PEG ratio of 1.89. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Retail - Restaurants industry was having an average PEG ratio of 1.94.
The Retail - Restaurants industry is part of the Retail-Wholesale sector. This industry, currently bearing a Zacks Industry Rank of 181, finds itself in the bottom 27% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
In the latest trading session, Onto Innovation (ONTO - Free Report) closed at $321.44, marking a +1.39% move from the previous day. This move outpaced the S&P 500's daily gain of 0.42%. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 0.29%.
Heading into today, shares of the maker of semiconductor manufacturing equipment had gained 4.44% over the past month, outpacing the Computer and Technology sector's gain of 0.85% and the S&P 500's gain of 2.2%.
Market participants will be closely following the financial results of Onto Innovation in its upcoming release. The company's upcoming EPS is projected at $1.68, signifying a 34.40% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $325.6 million, indicating a 28.39% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $7.14 per share and a revenue of $1.33 billion, indicating changes of +44.53% and +32.56%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Onto Innovation. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.41% upward. As of now, Onto Innovation holds a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Onto Innovation is currently trading at a Forward P/E ratio of 44.42. This represents no noticeable deviation compared to its industry average Forward P/E of 44.42.
It's also important to note that ONTO currently trades at a PEG ratio of 1.29. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Nanotechnology was holding an average PEG ratio of 1.29 at yesterday's closing price.
The Nanotechnology industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 1, which puts it in the top 1% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Symbotic Inc. (SYM - Free Report) closed at $43.64 in the latest trading session, marking a +1.14% move from the prior day. This change outpaced the S&P 500's 0.42% gain on the day. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq appreciated by 0.29%.
The stock of company has risen by 0.75% in the past month, lagging the Business Services sector's gain of 2.8% and the S&P 500's gain of 2.2%.
Analysts and investors alike will be keeping a close eye on the performance of Symbotic Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.12, signifying a 340.00% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $714.76 million, up 20.71% from the year-ago period.
SYM's full-year Zacks Consensus Estimates are calling for earnings of $0.5 per share and revenue of $2.79 billion. These results would represent year-over-year changes of -72.53% and +24.13%, respectively.
Investors might also notice recent changes to analyst estimates for Symbotic Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Symbotic Inc. is currently a Zacks Rank #5 (Strong Sell).
Digging into valuation, Symbotic Inc. currently has a Forward P/E ratio of 86.73. This signifies a premium in comparison to the average Forward P/E of 17.05 for its industry.
Meanwhile, SYM's PEG ratio is currently 2.89. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. SYM's industry had an average PEG ratio of 1.52 as of yesterday's close.
The Technology Services industry is part of the Business Services sector. This industry currently has a Zacks Industry Rank of 152, which puts it in the bottom 39% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow SYM in the coming trading sessions, be sure to utilize Zacks.com.
SentinelOne (S - Free Report) closed at $17.88 in the latest trading session, marking a -5.2% move from the prior day. This move lagged the S&P 500's daily gain of 0.42%. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq gained 0.29%.
The cybersecurity provider's shares have seen an increase of 27.78% over the last month, surpassing the Computer and Technology sector's gain of 0.85% and the S&P 500's gain of 2.2%.
Market participants will be closely following the financial results of SentinelOne in its upcoming release. It is anticipated that the company will report an EPS of $0.07, marking a 75% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $290.03 million, indicating a 19.76% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.36 per share and a revenue of $1.2 billion, representing changes of +80% and +19.89%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for SentinelOne. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.74% higher. At present, SentinelOne boasts a Zacks Rank of #2 (Buy).
In terms of valuation, SentinelOne is currently trading at a Forward P/E ratio of 52.84. This valuation marks a premium compared to its industry average Forward P/E of 51.92.
We can also see that S currently has a PEG ratio of 1.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Security industry held an average PEG ratio of 3.3.
The Security industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 109, placing it within the top 45% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Simply Good Foods (SMPL 1.85%) simply wasn't an inspiring stock on the last trading day of the week. On Friday, several analysts weighed in with new, post-earnings takes on the healthy comestibles company. These were mixed, but it was obvious that investors were leaning more toward the bearish updates than the more positive ones.
Slumping financials These came a day after Simply reported its fiscal third-quarter 2026 results. Net sales for the period were $357 million, down from the $381 million in the same period of fiscal 2025.
Image source: Getty Images.
On the bottom line, under generally accepted accounting principles (GAAP), the company flipped to a net loss of almost $52 million from the year-ago profit of over $41 million. On a non-GAAP (adjusted) and per-share basis, however, the story was different, with a profit of $0.42 down from third quarter 2025's $0.51.
Regardless, both line items well exceeded the consensus analyst estimates of under $333 million for net sales and $0.35 per share for adjusted net income.
Today's Change
(
-1.85
%) $
-0.24
Current Price
$
12.77
A flurry of Friday updates By my count, six analysts weighed in with Simply updates on Friday. Four of the half-dozen had a bearish tone, with one pundit going so far as to drastically cut his price target on the stock. This was Matt Curtis of DA Davidson, who now believes the shares are only worth $14 apiece, down from his previous $39. He maintained his existing Simply recommendation of neutral.
It's encouraging that the company, perhaps best known for its Atkins products that align with the namesake diet's requirements, did better than expected in the trailing quarter. Yet those top- and bottom-line erosions are concerning, and I'm not seeing many strong competitive advantages for Simply. Given that, I'd be more inclined to side with the more downbeat post-earnings takes.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Simply Good Foods. The Motley Fool has a disclosure policy.
On July 10, 2026, Comstock Resources Inc (CRK) shares fell 5.6% to $12.92. This decline follows a broader trend, with the stock down 44.3% year-to-date and trad
On July 10, 2026, Gulfport Energy Corp (GPOR) shares fell 5.2%, bringing the current price to $152.10. Over the past 52 weeks, the stock has traded between a hi
Natural gas company Gulfport Energy (GPOR 5.15%) wasn't providing much energy for its investors on Friday. Many of those folks were dissuaded by a bearish adjustment made by an analyst that morning and sold out of their stock, leaving it with a more than 5% loss that trading session.
Gloomy on gas? Truist Securities' Gabe Daoud cut his price target on Gulfport to $190 per share, some distance down from his previous fair value assessment of $219. That didn't change his overall view of the stock, as he maintained his hold recommendation.
Image source: Getty Images.
According to reports, Daoud's adjustment was part of a broader reevaluation of the natural gas exploration and production segment of the energy sector. His estimate for gas storage -- a crucial yardstick for pricing -- as of the end of this coming October anticipates it'll be 4% above the five-year norm. Typically, a higher volume of stored gas means lower sale prices.
Daoud did wax bullish about future periods, writing that 2028 and 2029 could see notably lower storage levels (and, therefore, higher prices for companies like Gulfport).
Today's Change
(
-5.15
%) $
-8.26
Current Price
$
152.10
Yet another surge in crude Another factor that's sure to affect natural gas prices is -- once again -- the rising price of crude oil, due largely to the recent flare-up in the Iran war. Typically, when crude increases, gas prices slide. The war will probably drag on for some time, so given that dynamic and the storage situation described by the analyst, I'd probably avoid natural gas equities for now.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Truist Financial. The Motley Fool has a disclosure policy.
On July 10, 2026, Boise Cascade Co (BCC) shares rose 5.3% to a current price of $76.06. The stock has seen a 52-week range of $65.00 to $95.00, illustrating sig
Activist investor Elliott Investment Management has built a large stake in CCC Intelligent Solutions , Bloomberg News reported on Friday, as the software firm explores a sale.
In the latest close session, Ralph Lauren (RL - Free Report) was up +1.89% at $394.90. The stock outpaced the S&P 500's daily gain of 0.42%. Meanwhile, the Dow gained 0.29%, and the Nasdaq, a tech-heavy index, added 0.29%.
The stock of upscale clothing company has fallen by 1.45% in the past month, lagging the Consumer Discretionary sector's gain of 0.02% and the S&P 500's gain of 2.2%.
Analysts and investors alike will be keeping a close eye on the performance of Ralph Lauren in its upcoming earnings disclosure. The company is forecasted to report an EPS of $4.26, showcasing a 13% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.86 billion, up 8.25% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $18.33 per share and a revenue of $8.66 billion, representing changes of +10.49% and +6.68%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Ralph Lauren. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.25% higher. Ralph Lauren is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Ralph Lauren's current valuation metrics, including its Forward P/E ratio of 21.14. This valuation marks a premium compared to its industry average Forward P/E of 15.73.
Investors should also note that RL has a PEG ratio of 1.92 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Textile - Apparel industry had an average PEG ratio of 2.14 as trading concluded yesterday.
The Textile - Apparel industry is part of the Consumer Discretionary sector. At present, this industry carries a Zacks Industry Rank of 191, placing it within the bottom 23% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Doximity (DOCS - Free Report) ended the recent trading session at $21.77, demonstrating a -1.09% change from the preceding day's closing price. This change lagged the S&P 500's 0.42% gain on the day. Meanwhile, the Dow gained 0.29%, and the Nasdaq, a tech-heavy index, added 0.29%.
Coming into today, shares of the medical social networking site had gained 9.94% in the past month. In that same time, the Medical sector gained 5.6%, while the S&P 500 gained 2.2%.
The investment community will be paying close attention to the earnings performance of Doximity in its upcoming release. The company is predicted to post an EPS of $0.29, indicating a 19.44% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $151.7 million, up 3.97% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.39 per share and a revenue of $670.18 million, signifying shifts of -8.55% and +3.93%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Doximity presently features a Zacks Rank of #5 (Strong Sell).
Valuation is also important, so investors should note that Doximity has a Forward P/E ratio of 15.79 right now. This valuation marks a discount compared to its industry average Forward P/E of 27.63.
Investors should also note that DOCS has a PEG ratio of 4.11 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 3.16.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 157, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
In the latest trading session, Viking Therapeutics, Inc. (VKTX - Free Report) closed at $38.86, marking a -5.54% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.42% for the day. On the other hand, the Dow registered a gain of 0.29%, and the technology-centric Nasdaq increased by 0.29%.
The company's shares have seen an increase of 43.8% over the last month, surpassing the Medical sector's gain of 5.6% and the S&P 500's gain of 2.2%.
Market participants will be closely following the financial results of Viking Therapeutics, Inc. in its upcoming release. The company is expected to report EPS of -$1.21, down 108.62% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$4.7 per share and a revenue of $0 million, demonstrating changes of -47.34% and 0%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Viking Therapeutics, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Viking Therapeutics, Inc. boasts a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 106, positioning it in the top 44% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Reddit Inc. (RDDT - Free Report) closed at $195.34 in the latest trading session, marking a -2.48% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.42%. Meanwhile, the Dow experienced a rise of 0.29%, and the technology-dominated Nasdaq saw an increase of 0.29%.
Shares of the company have appreciated by 15.61% over the course of the past month, outperforming the Computer and Technology sector's gain of 0.85%, and the S&P 500's gain of 2.2%.
The investment community will be closely monitoring the performance of Reddit Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on July 30, 2026. In that report, analysts expect Reddit Inc. to post earnings of $0.99 per share. This would mark year-over-year growth of 120%. Meanwhile, our latest consensus estimate is calling for revenue of $746.89 million, up 49.49% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $4.83 per share and a revenue of $3.25 billion, representing changes of +84.35% and +47.64%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Reddit Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Reddit Inc. is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note Reddit Inc.'s current valuation metrics, including its Forward P/E ratio of 41.45. Its industry sports an average Forward P/E of 19.73, so one might conclude that Reddit Inc. is trading at a premium comparatively.
The Internet - Software industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 92, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Lithium Americas Corp. (LAC - Free Report) closed the most recent trading day at $3.32, moving -6.74% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.42%. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq appreciated by 0.29%.
The lithium producer's shares have seen a decrease of 19.27% over the last month, not keeping up with the Basic Materials sector's loss of 4.07% and the S&P 500's gain of 2.2%.
Analysts and investors alike will be keeping a close eye on the performance of Lithium Americas Corp. in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.04, marking a 33.33% rise compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.14 per share and a revenue of $0 million, indicating changes of +69.57% and 0%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Lithium Americas Corp. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Lithium Americas Corp. boasts a Zacks Rank of #2 (Buy).
The Mining - Miscellaneous industry is part of the Basic Materials sector. With its current Zacks Industry Rank of 181, this industry ranks in the bottom 27% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
